Organogenesis Holdings Inc. Class A Common Stock
ORGOOrganogenesis Holdings Inc. Class A (ORGO) is a biotechnology company focused on developing and commercializing advanced regenerative medicine products. It specializes in tissue repair and wound management solutions derived from living cells and biological materials, aiming to improve outcomes in diverse medical fields such as surgical, wound care, and dental applications.
Company News
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. T...
The global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.
DJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.
Organogenesis Holdings reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not achieve statistical significance for its primary endpoint, causing the stock to drop 15.49%.
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
